Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA and Dasatinib for Metastatic Triple-Negative Inflammatory Breast Cancer
NCT05198843Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omega-3-acid triglycerides and dasatinib in inflammatory breast cancer (IBC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose up to 2 years and Overall Response Rate up to 2 years. Started Nov 2022; status: terminated.
02
Drugs
omega-3-acid triglyceridesdasatinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT05198843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198843.